Evidence map›Paper›PMID 40566684›Full record

ArticlePlant communications2025

The complete synthetic pathway of echinacoside from Cistanche deserticola and its de novo biosynthesis in yeast.

Yali Ban, Jixuan Jiang, Hongwang Yang, Haiyang Jia, Yaru Pang, Xu Cheng, Jianbin Yan, Qinggang Liao, Chun Li, Bo Lv and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Plant communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yali BanSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China.
Jixuan JiangSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China.
Hongwang YangSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China.
Haiyang JiaKey Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology/Institute of Biochemical Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 100081, China.
Yaru PangKey Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology/Institute of Biochemical Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 100081, China.
Xu ChengKey Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology/Institute of Biochemical Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 100081, China.
Jianbin YanAgricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen 518124, China.
Qinggang LiaoAgricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen 518124, China.
Chun LiKey Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology/Institute of Biochemical Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 100081, China; Key Lab for Industrial Biocatalysis, Ministry of Education, Department of Chemical Engineering, Tsinghua University, Beijing 100084, China. Electronic address: lichun@tsinghua.edu.cn.
Bo LvKey Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Ministry of Industry and Information Technology/Institute of Biochemical Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 100081, China. Electronic address: lv-b@bit.edu.cn.
Yongjun FengSchool of Life Science, Beijing Institute of Technology, Beijing 100081, China. Electronic address: fengyj@bit.edu.cn.

Funding

Non-US Government Research Support type
6 · The paper itself

Abstract

Echinacoside (ECH), a representative phenylethanol glycoside, exhibits diverse pharmacological properties and is used in the treatment of neurodegenerative disorders (e.g., Parkinson's and Alzheimer's diseases), ischemic brain injury, and cancer. The growing therapeutic demand for ECH has highlighted the need for scalable production. However, conventional methods face major limitations: chemical synthesis is hindered by the compound's structural complexity, and the yield of ECH extracted from plants is naturally low due to the host-dependent growth of Cistanche deserticola (C. deserticola), a parasitic desert plant. To establish a sustainable microbial production platform, we first deciphered the biosynthetic pathway of ECH in C. deserticola by integrating metabolomics analyses of plant tissues and callus cultures. This enabled the identification of key precursors, enzymatic steps, and regulatory mechanisms. Leveraging this knowledge, we engineered the pathway in Saccharomyces cerevisiae, achieving de novo ECH biosynthesis at a titer of 7.52 ± 1.42 mg/l. This study lays the foundation for industrial-scale ECH production and deepens our understanding of bioactive compound biosynthesis in parasitic plants, offering insights for future pathway engineering efforts.

Indexed as

CistancheGlycosidesSaccharomyces cerevisiaeBiosynthetic PathwaysMetabolic EngineeringechinacosideGlycosidesCistanche deserticoladifferential gene analysisEchinacosidemetabolomicsmicrobial biomanufacturing

Identifiers

PMID40566684
PMCPMC12447445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.